文献速递淋巴瘤白血病

慢性淋巴细胞白血病患者来源异种移植模型重现向Richter转化的克隆演化

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
PubMed 文献 · Leukemia · 2023-11-28

研究旨在建立患者来源异种移植(PDX)模型以研究慢性淋巴细胞白血病(CLL)和Richter转化(RT)的分子特征与演化。将CLL(PDX12)和RT(PDX19)细胞注入免疫缺陷NSG小鼠,两株PDX在形态和表型上均类似RT。全基因组测序显示PDX演化过程中出现前所未有的RT亚克隆异质性和克隆演化,PDX12的转化细胞来自CLL阶段已存在的极小的亚克隆。转录组分析显示PDX高氧化磷酸化(OXPHOS)和低B细胞受体(BCR)信号,与患者RT相似;OXPHOS抑制剂IACS-010759减少增殖并规避维奈克拉耐药。

要点

  • 成功建立两株RT-PDX模型,其中PDX12来源于CLL细胞并重现CLL向RT的演化。
  • PDX12转化细胞源自CLL阶段已存在的极小的亚克隆。
  • PDX显示高OXPHOS和低BCR信号,IACS-010759减少增殖并规避维奈克拉耐药。

核心结论

  • 建立了新的RT-PDX模型,其中一株来自CLL细胞,模拟了CLL向RT的演化,揭示了具有治疗价值的RT细胞内在特征。

研究设计与样本

  • 将CLL(PDX12)和RT(PDX19)细胞注入免疫缺陷NSG小鼠,建立患者来源异种移植(PDX)模型。
  • 对PDX演化不同时间点进行全基因组测序分析,并进行转录组分析。

主要发现

  • 两株PDX在形态和表型上均类似RT。
  • 全基因组测序显示PDX演化过程中的基因组景观与两例患者的RT肿瘤相似,并发现前所未有的RT亚克隆异质性和克隆演化。
  • PDX12中转化细胞从CLL阶段已存在的极小的亚克隆扩增而来。
  • 转录组分析显示PDX高OXPHOS和低BCR信号,与患者RT相似。
  • OXPHOS抑制剂IACS-010759减少增殖,并规避维奈克拉耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical behavior. In 5-10% of patients the disease transforms into a diffuse large-B cell lymphoma known as Richter transformation (RT), which is associated with dismal prognosis. Here, we aimed to establish patient-derived xenograft (PDX) models to study the molecular features and evolution of CLL and RT. We generated two PDXs by injecting CLL (PDX12) and RT (PDX19) cells into immunocompromised NSG mice. Both PDXs were morphologically and phenotypically similar to RT. Whole-genome sequencing analysis at different time points of the PDX evolution revealed a genomic landscape similar to RT tumors from both patients and uncovered an unprecedented RT subclonal heterogeneity and clonal evolution during PDX generation. In PDX12, the transformed cells expanded from a very small subclone already present at the CLL stage. Transcriptomic analysis of PDXs showed a high oxidative phosphorylation (OXPHOS) and low B-cell receptor (BCR) signaling similar to the RT in the patients. IACS-010759, an OXPHOS inhibitor, reduced proliferation, and circumvented resistance to venetoclax. In summary, we have generated new RT-PDX models, one of them from CLL cells that mimicked the evolution of CLL to RT uncovering intrinsic features of RT cells of therapeutical value.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Playa-Albinyana H, Arenas F, Royo R, et al. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation. Leukemia. 2023. PMID: 38017105. doi:10.1038/s41375-023-02095-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。